Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Psychiatry Res

Retrieve available abstracts of 365 articles:
HTML format

Single Articles

    June 2024
  1. ROTELLA F, Falone A, Cassioli E, Mannucci E, et al
    The effect of differences in trial design on estimates of efficacy of olanzapine in randomized studies.
    Psychiatry Res. 2024;336:115895.
    PubMed     Abstract available

    May 2024
  2. SANGIMINO M, Babbitt K, Lee HS, Park S, et al
    Bodily experiences of trauma and psychosis risk.
    Psychiatry Res. 2024;337:115961.
    PubMed     Abstract available

  3. OH H, Karcher NR, Li Verdugo J, Botello R, et al
    Ethno-racial disparities in psychosis-like experiences among students in higher education: Findings from the Healthy Minds Study 2020-2021.
    Psychiatry Res. 2024;337:115959.
    PubMed     Abstract available

  4. WU Y, Zhang CY, Zhang Y, Chen R, et al
    Genomic landscape and functional characterization of structural variations in schizophrenia and bipolar disorder.
    Psychiatry Res. 2024;337:115929.
    PubMed     Abstract available

  5. BULDUK BK, Tortajada J, Valiente-Palleja A, Callado LF, et al
    High number of mitochondrial DNA alterations in postmortem brain tissue of patients with schizophrenia compared to healthy controls.
    Psychiatry Res. 2024;337:115928.
    PubMed     Abstract available

    April 2024
  6. GUO H, Zhong S, Lam ST, Wang N, et al
    Trends in violent offending among people with schizophrenia: A 10-year ecological study.
    Psychiatry Res. 2024;337:115935.
    PubMed     Abstract available

  7. BRADLEY ER, Portanova J, Woolley JD, Buck B, et al
    Quantifying abnormal emotion processing: A novel computational assessment method and application in schizophrenia.
    Psychiatry Res. 2024;336:115893.
    PubMed     Abstract available

  8. SMITH LC, Mateos AC, Due AS, Bergstrom J, et al
    Immersive virtual reality in the treatment of auditory hallucinations: A PRISMA scoping review.
    Psychiatry Res. 2024;334:115834.
    PubMed     Abstract available

    March 2024
  9. SPINAZZOLA E, Quattrone D, Quattrone A, Murray RM, et al
    The increased incidence of psychosis during the COVID-19 pandemic in South London: The role of heavy cannabis use.
    Psychiatry Res. 2024;336:115869.

  10. HAMZEHPOUR L, Bohn T, Dutsch V, Jaspers L, et al
    From brain to body: exploring the connection between altered reward processing and physical fitness in schizophrenia.
    Psychiatry Res. 2024;335:115877.
    PubMed     Abstract available

  11. GALLEGO JA, McNamara RK, Blanco EA, Castaneda S, et al
    Evidence for cytokine dysregulation in schizophrenia spectrum disorders: A comparison of cerebrospinal fluid and blood samples.
    Psychiatry Res. 2024;335:115871.
    PubMed     Abstract available

  12. SEFIK E, Guest RM, Aberizk K, Espana R, et al
    Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity.
    Psychiatry Res. 2024;335:115867.
    PubMed     Abstract available

  13. SETHI S, Wakeham D, Ketter T, Hooshmand F, et al
    Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial.
    Psychiatry Res. 2024;335:115866.
    PubMed     Abstract available

  14. YANG H, Zhu D, Liu Y, Xu Z, et al
    Employing graph attention networks to decode psycho-metabolic interactions in Schizophrenia.
    Psychiatry Res. 2024;335:115841.
    PubMed     Abstract available

  15. KISHI T, Citrome L, Sakuma K, Iwata N, et al
    A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
    Psychiatry Res. 2024;333:115761.
    PubMed     Abstract available

    February 2024
  16. GORORA ME, Dalkner N, Moore RC, Depp CA, et al
    A meta-cognitive Wisconsin Card Sorting Test in people with schizophrenia and bipolar disorder: Self-assessment of sorting performance.
    Psychiatry Res. 2024;334:115831.
    PubMed     Abstract available

  17. QIN K, Yu Y, Cai H, Li J, et al
    Effectiveness of mindfulness-based intervention in schizophrenia: A meta-analysis of randomized controlled trials.
    Psychiatry Res. 2024;334:115808.
    PubMed     Abstract available

  18. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
    Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia.
    Psychiatry Res. 2024;334:115810.
    PubMed     Abstract available

  19. GOODING DC, Mohrbacher DA, Umucu E, Van Hulle CA, et al
    Ethnoracialized group differences in attitudes and knowledge about schizophrenia and willingness to engage in biomarker research: The UBIGR Study.
    Psychiatry Res. 2024;334:115776.
    PubMed     Abstract available

  20. HYATT AS, Mulvaney-Day N, Chow CM, Cook BL, et al
    Association between electronic nicotine product use and subsequent first episode psychosis.
    Psychiatry Res. 2024;334:115785.
    PubMed     Abstract available

  21. KWAK PP, Ibarra C, Hernandez A, Carrasco J, et al
    Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites.
    Psychiatry Res. 2024;334:115788.
    PubMed     Abstract available

  22. QUIRINO AHA, da Rocha MEC, Andrade AGM, E Souza FGM, et al
    The demonstrated association: Cannabis use and onset of psychosis in the study by Medeiros et al., refuting the reverse notion.
    Psychiatry Res. 2024;334:115771.

    January 2024
  23. HE R, Palominos C, Zhang H, Alonso-Sanchez MF, et al
    Navigating the semantic space: Unraveling the structure of meaning in psychosis using different computational language models.
    Psychiatry Res. 2024;333:115752.
    PubMed     Abstract available

  24. KOS C, Bais L, Klaasen N, Opmeer E, et al
    Effects of right prefrontal theta-burst transcranial magnetic stimulation or transcranial direct current stimulation on apathy in patients with schizophrenia: A multicenter RCT.
    Psychiatry Res. 2024;333:115743.
    PubMed     Abstract available

  25. YI S, Wang Q, Wang W, Hong C, et al
    Efficacy of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms and cognitive functioning in schizophrenia: An umbrella review of systematic reviews and meta-analyses.
    Psychiatry Res. 2024;333:115728.
    PubMed     Abstract available

  26. TOUMAIAN M, Covanis P, Mantas A, Karantinos T, et al
    Multisensory integration deficits in Schizophrenia and Autism evidenced in behaviour but not event related potentials.
    Psychiatry Res. 2024;332:115727.
    PubMed     Abstract available

  27. PROHENS L, Rodriguez N, Segura AG, Martinez-Pinteno A, et al
    Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.
    Psychiatry Res. 2024;332:115722.
    PubMed     Abstract available

  28. JEROME L, Matanov A, Bird V, Priebe S, et al
    Comparison of subjective quality of life domains in schizophrenia, mood, and anxiety disorders; an individual patient data meta-analysis.
    Psychiatry Res. 2024;332:115707.
    PubMed     Abstract available

  29. CHU RST, Chong RCH, Chang DHH, Shan Leung AL, et al
    The risk of stroke and post-stroke mortality in people with schizophrenia: A systematic review and meta-analysis study.
    Psychiatry Res. 2024;332:115713.
    PubMed     Abstract available

  30. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Ojeda N, et al
    Premorbid adjustment as predictor of long-term functionality: Findings from a 10-year follow-up study in the PAFIP-cohort.
    Psychiatry Res. 2024;331:115674.
    PubMed     Abstract available

  31. MASTELLARI T, Saint-Dizier C, Fovet T, Geoffroy PA, et al
    Exploring seasonality in catatonia diagnosis: Evidence from a large-scale population study.
    Psychiatry Res. 2024;331:115652.
    PubMed     Abstract available

    December 2023
  32. WANG Y, Zhang X
    The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia.
    Psychiatry Res. 2023;332:115708.
    PubMed     Abstract available

  33. VGONTZAS AN, Paschalidou A, Simos PG, Anastasaki M, et al
    Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder.
    Psychiatry Res. 2023;332:115676.
    PubMed     Abstract available

    Did the human genome project affect research on Schizophrenia?
    Psychiatry Res. 2023;333:115691.
    PubMed     Abstract available

  35. KIM WS, Shen J, Tsogt U, Odkhuu S, et al
    Altered thalamic volumes and functional connectivity in the recovered patients with psychosis.
    Psychiatry Res. 2023;331:115688.
    PubMed     Abstract available

  36. ZHOU D, Xie H, Chen L, Zhu Z, et al
    The cognitive improvement in patients with schizophrenia following low-intensity repetitive transcranial magnetic stimulation could last for 6 months: A randomized controlled trial.
    Psychiatry Res. 2023;332:115672.
    PubMed     Abstract available

  37. CHEN Y, Zhang L, Sun Y, Wang W, et al
    Prevalence of constipation in patients with schizophrenia: A systematic review and meta-analysis.
    Psychiatry Res. 2023;331:115659.

  38. DE MEDEIROS MW, Andrade JC, Haddad NM, Mendonca M, et al
    Cannabis use influences disorganized symptoms severity but not transition in a cohort of non-help-seeking individuals at-risk for psychosis from Sao Paulo, Brazil.
    Psychiatry Res. 2023;331:115665.
    PubMed     Abstract available

  39. DEAN B, Duce J, Li QX, Masters CL, et al
    Lower levels of soluble beta-amyloid precursor protein, but not beta-amyloid, in the frontal cortex in schizophrenia.
    Psychiatry Res. 2023;331:115656.
    PubMed     Abstract available

  40. FENG XZ, Li Z, Li ZY, Wang K, et al
    Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis.
    Psychiatry Res. 2023;332:115637.
    PubMed     Abstract available

    Harnessing neuroplasticity.
    Psychiatry Res. 2023;330:115607.
    PubMed     Abstract available

  42. STAFFORD E, Jakob S, Gur RE, Corcoran CM, et al
    Securing direct stakeholder feedback to inform clinical research in serious mental illness: Results of a patient and family perspectives survey.
    Psychiatry Res. 2023;330:115574.
    PubMed     Abstract available

    November 2023
  43. GROENING JM, Denton E, Parvaiz R, Brunet DL, et al
    A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses.
    Psychiatry Res. 2023;331:115626.
    PubMed     Abstract available

  44. LAMANNA-RAMA N, Romero-Miguel D, Casquero-Veiga M, MacDowell KS, et al
    THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation.
    Psychiatry Res. 2023;331:115643.
    PubMed     Abstract available

  45. WEI Z, Wang Y, Hu L, Wang Y, et al
    Incidence, prevalence, and mortality of schizophrenia from 2016 to 2020 in Shandong, China.
    Psychiatry Res. 2023;331:115612.
    PubMed     Abstract available

  46. LEE J, Xue X, Au E, McIntyre WB, et al
    Central insulin dysregulation in antipsychotic-naive first-episode psychosis: In silico exploration of gene expression signatures.
    Psychiatry Res. 2023;331:115636.
    PubMed     Abstract available

  47. CUESTA MJ, Gil-Berrozpe GJ, Sanchez-Torres AM, Moreno-Izco L, et al
    20-Year trajectories of six psychopathological dimensions in patients with first-episode psychosis: Could they be predicted?
    Psychiatry Res. 2023;331:115614.
    PubMed     Abstract available

  48. HU Q, Jiao X, Zhou J, Tang Y, et al
    Low-frequency repetitive transcranial magnetic stimulation over the right orbitofrontal cortex for patients with first-episode schizophrenia: A randomized, double-blind, sham-controlled trial.
    Psychiatry Res. 2023;330:115600.
    PubMed     Abstract available

  49. BOGE K, Hallford DJ, Pillny M
    Mindfulness, psychological flexibility and their relationship with psychopathology in persons with schizophrenia-spectrum-disorders and healthy controls - A multicenter cross-sectional study.
    Psychiatry Res. 2023;330:115591.
    PubMed     Abstract available

  50. DAZZAN P
    Disentangling psychosis: The challenges of informing precision medicine for what is not a single disorder.
    Psychiatry Res. 2023;330:115596.
    PubMed     Abstract available

  51. BERNARDIN F, Gauld C, Martin VP, Laprevote V, et al
    The 68 symptoms of the clinical high risk for psychosis: Low similarity among fourteen screening questionnaires.
    Psychiatry Res. 2023;330:115592.
    PubMed     Abstract available

  52. CORNBLATT BA, McFarlane WR, Carrion RE
    Authors' reply to comments on: Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
    Psychiatry Res. 2023;330:115594.

  53. KIRSHENBAUM AP, Sofis MJ, Slade M
    Response to recreational cannabis use over time in individuals at clinical high risk for psychosis: lack of associations with symptom, neurocognitive, functioning, and treatment patterns by Carrion et al., 2023.
    Psychiatry Res. 2023;330:115589.

  54. PARK S
    Schizophrenia in the mind, the brain and the body.
    Psychiatry Res. 2023;329:115547.
    PubMed     Abstract available

    October 2023
  55. BIRONG CHEN, Tan XW, Tor PC
    The impact of the number of previous illness episodes on early response to electroconvulsive therapy (ECT) in psychosis, mania, depression, psychotic depression, and catatonia: A naturalistic transdiagnostic analysis.
    Psychiatry Res. 2023;330:115580.
    PubMed     Abstract available

  56. KIM HK, Goncalves VF, Husain MI, Muller DJ, et al
    Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.
    Psychiatry Res. 2023;330:115563.
    PubMed     Abstract available

  57. LIN CH, Huang CJ, Lin TC, Chan HY, et al
    Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
    Psychiatry Res. 2023;330:115575.
    PubMed     Abstract available

  58. WANG P, Jiang Y, Hoptman MJ, Li Y, et al
    Structural-functional connectivity deficits of callosal-white matter-cortical circuits in schizophrenia.
    Psychiatry Res. 2023;330:115559.
    PubMed     Abstract available

  59. VAN DER TUIN S, Booij SH, Muller MK, van den Berg D, et al
    The added value of daily diary data in 1- and 3-year prediction of psychopathology and psychotic experiences in individuals at risk for psychosis.
    Psychiatry Res. 2023;329:115546.
    PubMed     Abstract available

  60. HASSAN L, Eisner E, Berry K, Emsley R, et al
    User engagement in a randomised controlled trial for a digital health intervention for early psychosis (Actissist 2.0 trial).
    Psychiatry Res. 2023;329:115536.
    PubMed     Abstract available

  61. SCHLIEF M, Rich N, Rains LS, Baldwin H, et al
    Ethnic differences in receipt of psychological interventions in Early Intervention in Psychosis services in England - a cross-sectional study.
    Psychiatry Res. 2023;330:115529.
    PubMed     Abstract available

  62. ZHANG T, Xu L, Wei Y, Tang X, et al
    Duration of untreated prodromal psychosis among individuals with clinical high risk for psychosis.
    Psychiatry Res. 2023;329:115522.
    PubMed     Abstract available

    September 2023
  63. SAMPEDRO A, Pena J, Sanchez P, Ibarretxe-Bilbao N, et al
    Moderators of functional improvement after integrative cognitive remediation in schizophrenia: Toward a personalized treatment approach.
    Psychiatry Res. 2023;329:115495.
    PubMed     Abstract available

  64. HUI CLM, Wong CCL, Chan EWT, Suen YN, et al
    COVID-19 exposure and psychosis: A comparison of clinical, functional, and cognitive profiles in remitted patients with psychosis.
    Psychiatry Res. 2023;328:115487.
    PubMed     Abstract available

  65. CAMPRODON-BOADAS P, De la Serna E, Plana MT, Flamarique I, et al
    Delusional beliefs in adolescents with anorexia nervosa, obsessive-compulsive disorder, or first-episode psychosis: A comparative study.
    Psychiatry Res. 2023;328:115490.
    PubMed     Abstract available

  66. BALDINI V, Stefano RD, Rindi LV, Ahmed AO, et al
    Association between adverse childhood experiences and suicidal behavior in schizophrenia spectrum disorders: A systematic review and meta-analysis.
    Psychiatry Res. 2023;329:115488.
    PubMed     Abstract available

  67. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
    Introducing an interview-based cognitive assessment tool for people with Schizophrenia in Ethiopia.
    Psychiatry Res. 2023;328:115474.
    PubMed     Abstract available

  68. SANCHEZ-TORRES AM, Garcia de Jalon E, Gil-Berrozpe GJ, Peralta V, et al
    Cognitive intraindividual variability, cognitive impairment and psychosocial functioning in first-episode psychosis patients.
    Psychiatry Res. 2023;328:115473.
    PubMed     Abstract available

  69. FORDHAM E, Gao CX, Filia K, O'Donoghue B, et al
    Social disadvantage in early psychosis and its effect on clinical presentation and service access, engagement and use.
    Psychiatry Res. 2023;328:115478.
    PubMed     Abstract available

  70. MAURUS I, Roell L, Lembeck M, Papazova I, et al
    Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial.
    Psychiatry Res. 2023;328:115480.
    PubMed     Abstract available

  71. INCHAUSTI L, Gorostiza I, Gonzalez Torres MA, Oraa R, et al
    The transition to Schizophrenia spectrum disorder from a first psychotic episode that did or did not appear to be induced by substance use.
    Psychiatry Res. 2023;328:115475.
    PubMed     Abstract available

  72. FANG X, Gao C, Wu W, Hu X, et al
    The role of the gut microbiome in weight-gain in schizophrenia patients treated with atypical antipsychotics: Evidence based on altered composition and function in a cross-sectional study.
    Psychiatry Res. 2023;328:115463.
    PubMed     Abstract available

  73. ZHANG J, Yang Y, Liu T, Shi Z, et al
    Functional connectivity in people at clinical and familial high risk for schizophrenia.
    Psychiatry Res. 2023;328:115464.
    PubMed     Abstract available

  74. SMITH ECC, Au E, Pereira S, Sharma E, et al
    Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review.
    Psychiatry Res. 2023;328:115472.
    PubMed     Abstract available

  75. LUCKHOFF HK, Asmal L, Smit R, Phahladira L, et al
    Sex, gender, and outcome in first-episode psychosis: The role of premorbid functioning.
    Psychiatry Res. 2023;328:115460.
    PubMed     Abstract available

  76. SEGAL SP, Rimes L, Badran L
    Crime and victimization outcomes following civil rights limits to the use of compulsory treatment.
    Psychiatry Res. 2023;327:115377.
    PubMed     Abstract available

  77. JOSHI YB, Gonzalez CE, Molina JL, MacDonald LR, et al
    Mismatch negativity predicts initial auditory-based targeted cognitive training performance in a heterogeneous population across psychiatric disorders.
    Psychiatry Res. 2023;327:115215.
    PubMed     Abstract available

  78. XIE Y, Guan M, Wang Z, Ma Z, et al
    Alterations in brain connectivity patterns in schizophrenia patients with auditory verbal hallucinations during low frequency repetitive transcranial magnetic stimulation.
    Psychiatry Res. 2023;328:115457.
    PubMed     Abstract available

    August 2023
  79. KUUSKMAE C, Philips MA, Kilk K, Haring L, et al
    Kynurenine pathway dynamics in patients with schizophrenia spectrum disorders across the disease trajectory.
    Psychiatry Res. 2023;328:115423.
    PubMed     Abstract available

  80. CARRION RE, Auther AM, McLaughlin D, Adelsheim S, et al
    Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
    Psychiatry Res. 2023;328:115420.
    PubMed     Abstract available

  81. ZHANG Y, Lu Z, Sun Y, Zhang X, et al
    Predictive role of pulvinar in social functional outcome of schizophrenia.
    Psychiatry Res. 2023;327:115419.
    PubMed     Abstract available

  82. JOHANSSON M, Hjarthag F, Helldin L
    Exploring cross-sectional and longitudinal symptomatic remission and subjective quality of life in schizophrenia.
    Psychiatry Res. 2023;328:115421.
    PubMed     Abstract available

  83. FEKIH-ROMDHANE F, Abassi B, Ghrissi F, Loch AA, et al
    Suicide risk among individuals at Ultra-High Risk (UHR) of psychosis in a developing North African country: A 12-month naturalistic prospective cohort study from the TRIP project.
    Psychiatry Res. 2023;327:115409.
    PubMed     Abstract available

  84. ALEKSANDROWICZ A, Kowalski J, Stefaniak I, Elert K, et al
    Cognitive correlates of auditory hallucinations in schizophrenia spectrum disorders.
    Psychiatry Res. 2023;327:115372.
    PubMed     Abstract available

  85. LIU X, Xu L, Gong J, Ye Q, et al
    The effect of high-dose accelerated continuous theta burst stimulation (cTBS) treatment on auditory verbal hallucinations (AVH): A pilot study.
    Psychiatry Res. 2023;326:115337.

  86. LOCH AA, Pinto MTC, Andrade JC, de Jesus LP, et al
    Plasma levels of neurotrophin 4/5, NGF and pro-BDNF influence transition to mental disorders in a sample of individuals at ultra-high risk for psychosis.
    Psychiatry Res. 2023;327:115402.
    PubMed     Abstract available

    July 2023
  87. HEMAGER N, Gregersen M, Christiani CJ, Hjorthoj C, et al
    Development of social functioning in preadolescent children at familial high-risk of schizophrenia or bipolar disorder - a 4-year follow-up study from age 7 to 11.
    Psychiatry Res. 2023;327:115397.
    PubMed     Abstract available

  88. DAI J, Zhang MZ, He QQ, Chen R, et al
    The emerging role of exosomes in Schizophrenia.
    Psychiatry Res. 2023;327:115394.
    PubMed     Abstract available

  89. KONDRATYEV NV, Alfimova MV, Kaleda VG, Lezheiko TV, et al
    Assessing the impact of the de novo SLC6A1 mutation in schizophrenia through a comprehensive case study.
    Psychiatry Res. 2023;327:115399.

  90. ZHANG T, Wei Y, Cui H, Tang X, et al
    Associations between age and neurocognition in individuals at clinical high risk and first-episode psychosis.
    Psychiatry Res. 2023;327:115385.
    PubMed     Abstract available

  91. WANG C, Tishler TA, Nuechterlein KH, Ellingson BM, et al
    Cortical thickness, gray-white matter contrast, and intracortical myelin in first-episode schizophrenia patients treated with long-acting paliperidone palmitate versus oral antipsychotics.
    Psychiatry Res. 2023;326:115364.
    PubMed     Abstract available

    June 2023
  92. CHEN X, Tan W, Cheng Y, Huang D, et al
    Polygenic risk for schizophrenia and the language network: Putative compensatory reorganization in unaffected siblings.
    Psychiatry Res. 2023;326:115319.
    PubMed     Abstract available

  93. PANARIELLO F, Zamparini M, Picchioni M, Nielssen OB, et al
    Exposure to violence in childhood and risk of violence in adult schizophrenia: Results from a multinational study.
    Psychiatry Res. 2023;326:115299.
    PubMed     Abstract available

  94. CHU RYK, Wei Y, Osborn DP, Ng VWS, et al
    Breast cancer risks following antipsychotic use in women with bipolar disorder versus schizophrenia: A territory-wide nested case-control study spanning two decades.
    Psychiatry Res. 2023;326:115287.
    PubMed     Abstract available

  95. OKADA H, Sawamura D, Kunita K, Ogasawara H, et al
    Prefrontal activation during simulated driving in people with schizophrenia: A functional near-infrared spectroscopy study.
    Psychiatry Res. 2023;326:115285.
    PubMed     Abstract available

    May 2023
  96. VEDDUM L, Greve AN, Gregersen M, Andreassen AK, et al
    A study of the genetic architecture of social responsiveness in families with parental schizophrenia or bipolar disorder and population-based controls.
    Psychiatry Res. 2023;326:115280.
    PubMed     Abstract available

  97. TATAR O, Abdel-Baki A, Dyachenko A, Bakouni H, et al
    Evaluating preferences for online psychological interventions to decrease cannabis use in young adults with psychosis: An observational study.
    Psychiatry Res. 2023;326:115276.
    PubMed     Abstract available

  98. LEE JJ, Piras E, Tamburini S, Bu K, et al
    Gut and oral microbiome modulate molecular and clinical markers of schizophrenia-related symptoms: A transdiagnostic, multilevel pilot study.
    Psychiatry Res. 2023;326:115279.
    PubMed     Abstract available

  99. SHADOWEN N, Meehan Z, Webb C, Fowles T, et al
    Early intervention in youth psychosis: Novel approaches to understanding change.
    Psychiatry Res. 2023;326:115269.
    PubMed     Abstract available

  100. COHN J
    Elaboration of some points in "The association of gender dysphoria with psychosis".
    Psychiatry Res. 2023;325:115264.

  101. LI Q, Gong Y, Cui Y, Cheng C, et al
    Efficacy of transcutaneous electrical acupoint stimulation for patients with first-episode schizophrenia: An 8-week, preliminary, randomized controlled trial.
    Psychiatry Res. 2023;325:115255.
    PubMed     Abstract available

  102. WOJTALIK JA, Brown WJ, Mesholam-Gately RI, Kotwani A, et al
    Predictors of treatment discontinuation during an 18-month multi-site randomized trial of Cognitive Enhancement Therapy for early course schizophrenia.
    Psychiatry Res. 2023;326:115254.
    PubMed     Abstract available

  103. CIAMPELLI S, Voppel AE, de Boer JN, Koops S, et al
    Combining automatic speech recognition with semantic natural language processing in schizophrenia.
    Psychiatry Res. 2023;325:115252.
    PubMed     Abstract available

  104. ZHANG H, Parola A, Zhou Y, Wang H, et al
    Linguistic markers of psychosis in Mandarin Chinese: Relations to theory of mind.
    Psychiatry Res. 2023;325:115253.
    PubMed     Abstract available

  105. REICH N, Delavari F, Schneider M, Thillainathan N, et al
    Multivariate patterns of disrupted sleep longitudinally predict affective vulnerability to psychosis in 22q11.2 Deletion Syndrome.
    Psychiatry Res. 2023;325:115230.
    PubMed     Abstract available

  106. SANCHEZ RUIZ JA, Coombes BJ, Pendegraft RS, Ozerdem A, et al
    Pharmacotherapy exposure as a marker of disease complexity in bipolar disorder: Associations with clinical & genetic risk factors.
    Psychiatry Res. 2023;323:115174.
    PubMed     Abstract available

  107. BUCK B, Wingerson M, Chander A, Tauscher JS, et al
    A preliminary study examining terminology used by individuals with lived experience describing beliefs about being targeted or harmed by others.
    Psychiatry Res. 2023;323:115129.
    PubMed     Abstract available

    April 2023
  108. FUNG VSC, Chan JCY, Wong SCY, Wong CSM, et al
    Investigation of momentary negative symptoms in patients with early psychosis in daily life: An experience sampling study.
    Psychiatry Res. 2023;325:115234.
    PubMed     Abstract available

  109. TOLL A, Pechuan E, Berge D, Legido T, et al
    Factors associated with suicide attempts in first-episode psychosis during the first two years after onset.
    Psychiatry Res. 2023;325:115232.
    PubMed     Abstract available

  110. BENUTO LT, Done M, Zepeda M, Fitzgerald J, et al
    A systematic review of persons of color participation in first episode psychosis coordinated specialty care randomized controlled trials in North America.
    Psychiatry Res. 2023;325:115221.
    PubMed     Abstract available

  111. TROTTI RL, Parker DA, Sabatinelli D, Keshavan MS, et al
    Emotional scene processing in biotypes of psychosis.
    Psychiatry Res. 2023;324:115227.
    PubMed     Abstract available

  112. LU Z, Zhang Y, Sun Y, Liao Y, et al
    The positive association between antipsychotic-induced weight gain and therapeutic response: New biotypes of schizophrenia.
    Psychiatry Res. 2023;324:115226.
    PubMed     Abstract available

  113. O'CONNELL KS, Koch E, Lenk HC, Akkouh IA, et al
    Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
    Psychiatry Res. 2023;325:115217.
    PubMed     Abstract available

  114. DE THURAH L, Kiekens G, Sips R, Teixeira A, et al
    Using Experience Sampling Methods to support clinical management of psychosis: The perspective of people with lived experience.
    Psychiatry Res. 2023;324:115207.
    PubMed     Abstract available

  115. ELVEVAG B
    Reflections on measuring disordered thoughts as expressed via language.
    Psychiatry Res. 2023;322:115098.
    PubMed     Abstract available

  116. TONYALI A, Karacetin G, Ocakoglu BK, Atay A, et al
    Development and validation of Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) for Internet Gaming Disorder (IGD) and factor analytic assessment.
    Psychiatry Res. 2023;324:115187.
    PubMed     Abstract available

    March 2023
  117. FUSAR-POLI L, Prachason T, Erzin G, Pries LK, et al
    Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.
    Psychiatry Res. 2023;323:115184.
    PubMed     Abstract available

  118. GARRIDO-TORRES N, Alameda L, Suarez MLS, Rocha Gonzalez I, et al
    Corrigendum "Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain" [Psychiatry Res. 308 (2022) 114352].
    Psychiatry Res. 2023 Mar 27:115146. doi: 10.1016/j.psychres.2023.115146.

  119. XU H, Zhou Y, Wang J, Liang Z, et al
    Effect of HD-tDCS on white matter integrity and associated cognitive function in chronic schizophrenia: A double-blind, sham-controlled randomized trial.
    Psychiatry Res. 2023;324:115183.
    PubMed     Abstract available

  120. SUEN YN, Pang SWT, Cheung C, Wong TY, et al
    Impact of early negative symptom patterns on the long-term outcomes of patients with first-episode schizophrenia-spectrum disorders: A 12-year follow up study.
    Psychiatry Res. 2023;323:115180.
    PubMed     Abstract available

  121. POLETTI M, Pelizza L, Loas G, Azzali S, et al
    Anhedonia and suicidal ideation in young people with early psychosis: Further findings from the 2-year follow-up of the ReARMS program.
    Psychiatry Res. 2023;323:115177.
    PubMed     Abstract available

  122. TUCCI AA, Schroeder A, Noel C, Shvetz C, et al
    Social cognition in youth with a first-degree relative with schizophrenia: A systematic scoping review.
    Psychiatry Res. 2023;323:115173.
    PubMed     Abstract available

  123. PETKARI E
    Can we really define the effect of psychological interventions on Quality of Life for patients with schizophrenia based on the most recent meta-analysis in the field?
    Psychiatry Res. 2023 Mar 20:115149. doi: 10.1016/j.psychres.2023.115149.

  124. GOUSE BM, Boliver EE, Oblath R, Camacho L, et al
    Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits.
    Psychiatry Res. 2023;323:115151.
    PubMed     Abstract available

  125. AIREY ND, Taylor CDJ, Vikram A, Berry K, et al
    Trauma measures for use with psychosis populations: A systematic review of psychometric properties using COSMIN.
    Psychiatry Res. 2023;323:115163.
    PubMed     Abstract available

  126. MEDALIA A, Saperstein A, Javitt DC, Qian M, et al
    Feasibility and clinical utility of using the tone matching test for assessment of early auditory processing in schizophrenia.
    Psychiatry Res. 2023;323:115152.
    PubMed     Abstract available

  127. PALMA-ALVAREZ RF, Daigre C, Ros-Cucurull E, Perea-Ortueta M, et al
    Clinical features and factors related to lifetime suicidal ideation and suicide attempts in patients who have had substance-induced psychosis across their lifetime.
    Psychiatry Res. 2023;323:115147.
    PubMed     Abstract available

  128. LIN BD, Vermeulen JM, Bolhuis K, Chang X, et al
    Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls.
    Psychiatry Res. 2023;323:115143.
    PubMed     Abstract available

  129. FIVEL L, Mondino M, Brunelin J, Haesebaert F, et al
    Basic auditory processing and its relationship with symptoms in patients with schizophrenia: A systematic review.
    Psychiatry Res. 2023;323:115144.
    PubMed     Abstract available

  130. XIE M, Cai J, Liu Y, Wei W, et al
    Association between childhood trauma and white matter deficits in first-episode schizophrenia.
    Psychiatry Res. 2023;323:115111.
    PubMed     Abstract available

  131. VEDDUM L, Gregersen M, Andreassen AK, Knudsen CB, et al
    Social responsiveness in families with parental schizophrenia or bipolar disorder-The Danish High Risk and Resilience Study.
    Psychiatry Res. 2023;323:115140.
    PubMed     Abstract available

  132. TAVARES VDO, Rossell SL, Schuch FB, Herring M, et al
    Effects of exercise on cognitive functioning in adults with serious mental illness: A meta analytic review.
    Psychiatry Res. 2023;321:115081.
    PubMed     Abstract available

    From communication dysfunction to treatment options in serious mental illness.
    Psychiatry Res. 2023;321:115062.
    PubMed     Abstract available

  134. DO KQ
    Bridging the gaps towards precision psychiatry: Mechanistic biomarkers for early detection and intervention.
    Psychiatry Res. 2023;321:115064.
    PubMed     Abstract available

  135. DUBOURG L, Kojovic N, Eliez S, Schaer M, et al
    Visual processing of complex social scenes in 22q11.2 deletion syndrome: Relevance for negative symptoms.
    Psychiatry Res. 2023;321:115074.
    PubMed     Abstract available

  136. CAI J, Li L, Shao T, Sun M, et al
    Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
    Psychiatry Res. 2023;322:115138.
    PubMed     Abstract available

    February 2023
  137. PONCE-CORREA F, Caqueo-Urizar A, Berrios R, Escobar-Soler C, et al
    Defining recovery in schizophrenia: A review of outcome studies.
    Psychiatry Res. 2023;322:115134.
    PubMed     Abstract available

  138. WANG Y, Wang J, Su W, Hu H, et al
    Symptom-circuit mappings of the schizophrenia connectome.
    Psychiatry Res. 2023;323:115122.
    PubMed     Abstract available

  139. MA X, Yang WFZ, Zheng W, Li Z, et al
    Neuronal dysfunction in individuals at early stage of schizophrenia, A resting-state fMRI study.
    Psychiatry Res. 2023;322:115123.
    PubMed     Abstract available

  140. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
    A clinical staging model of psychotic disorders based on a long-term follow-up of first-admission psychosis: A validation study.
    Psychiatry Res. 2023;322:115109.
    PubMed     Abstract available

  141. ROMEO B, Willaime L, Rari E, Benyamina A, et al
    Efficacy of 5-HT2A antagonists on negative symptoms in patients with schizophrenia: A meta-analysis.
    Psychiatry Res. 2023;321:115104.
    PubMed     Abstract available

  142. STEFFENSEN NL, Hemager N, Bundgaard AF, Gantriis DL, et al
    Affective lability in parents with schizophrenia or bipolar disorder and their co-parents - The Danish High Risk and Resilience Study VIA 7.
    Psychiatry Res. 2023;321:115092.
    PubMed     Abstract available

  143. DUDLEY R, Denton S, Mathewson J, Pervez S, et al
    Prevalence of multisensory hallucinations in people at risk of transition to psychosis.
    Psychiatry Res. 2023;322:115091.
    PubMed     Abstract available

  144. LUO G, Li Y, Yao C, Li M, et al
    Duration of untreated illness and clinical correlates in first-episode and drug-naive patients with major depressive disorder.
    Psychiatry Res. 2023;320:115056.
    PubMed     Abstract available

  145. AAS M, Ueland T, Lagerberg TV, Melle I, et al
    Retrospectively assessed childhood trauma experiences are associated with illness severity in mental disorders adjusted for symptom state.
    Psychiatry Res. 2023;320:115045.
    PubMed     Abstract available

  146. OLAYA B, Moneta MV, Plana-Ripoll O, Haro JM, et al
    Association between mental disorders and mortality: A register-based cohort study from the region of Catalonia.
    Psychiatry Res. 2023;320:115037.
    PubMed     Abstract available

    January 2023
  147. KIM AM, Sohn JH
    The impact of the Mental Health Act revision for deinstitutionalization in Korea on the crime rate of people with schizophrenia.
    Psychiatry Res. 2023;321:115089.
    PubMed     Abstract available

  148. TAN EJ, Neill E, Kleiner JL, Rossell SL, et al
    Depressive symptoms are specifically related to speech pauses in schizophrenia spectrum disorders.
    Psychiatry Res. 2023;321:115079.
    PubMed     Abstract available

  149. BORKENT J, Ioannou M, Folkertsma TS, Wardenaar KJ, et al
    Serum free thiols in recently diagnosed patients with schizophrenia spectrum disorder: A potentially useful biomarker of oxidative stress.
    Psychiatry Res. 2023;321:115075.
    PubMed     Abstract available

  150. ESPOSITO CM, Biagianti B, D'Agostino A, Dell'Osso B, et al
    First episode psychosis during the Covid-19 pandemic in Milan, Italy: Diagnostic outcomes at 1-year follow-up.
    Psychiatry Res. 2023;321:115068.
    PubMed     Abstract available

  151. SONG M, Liu Y, Zhou J, Shi H, et al
    Potential plasma biomarker panels identification for the diagnosis of first-episode schizophrenia and monitoring antipsychotic monotherapy with the use of metabolomics analyses.
    Psychiatry Res. 2023;321:115070.
    PubMed     Abstract available

  152. RICCI V, Ceci F, Di Carlo F, Di Muzio I, et al
    First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
    Psychiatry Res. 2023;320:115053.
    PubMed     Abstract available

  153. MINOR KS, Lundin NB, Myers EJ, Fernandez-Villardon A, et al
    Automated measures of speech content and speech organization in schizophrenia: Test-retest reliability and generalizability across demographic variables.
    Psychiatry Res. 2023;320:115048.
    PubMed     Abstract available

  154. Letter to Editor regarding "Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain".
    Psychiatry Res. 2023;322:115016.

    Estrogen - A key neurosteroid in the understanding and treatment of mental illness in women.
    Psychiatry Res. 2023;319:114991.
    PubMed     Abstract available

  156. MOTA NB
    How can computational tools help to understand language patterns in mental suffering considering social diversity.
    Psychiatry Res. 2023;319:114995.
    PubMed     Abstract available

    December 2022
  157. DELISI LE
    Brain plasticity, language anomalies, genetic risk and the patient with schizophrenia: Trajectory of change over a lifetime. A commentary.
    Psychiatry Res. 2022;320:115034.
    PubMed     Abstract available

    Negative symptoms of schizophrenia: Trying to answer unanswered research questions.
    Psychiatry Res. 2022;320:115043.
    PubMed     Abstract available

  159. LI L, Rami FZ, Lee BM, Kim WS, et al
    Predictors of full recovery in patients with early stage schizophrenia spectrum disorders.
    Psychiatry Res. 2022;320:115035.
    PubMed     Abstract available

  160. JIN Y, Tong J, Huang Y, Shi D, et al
    Effectiveness of accelerated intermittent theta burst stimulation for social cognition and negative symptoms among individuals with schizophrenia: A randomized controlled trial.
    Psychiatry Res. 2022;320:115033.
    PubMed     Abstract available

  161. PENA-GARIJO J, Lacruz M, Masanet MJ, Palop-Grau A, et al
    Specific facial emotion recognition deficits across the course of psychosis: A comparison of individuals with low-risk, high-risk, first-episode psychosis and multi-episode schizophrenia-spectrum disorders.
    Psychiatry Res. 2022;320:115029.
    PubMed     Abstract available

  162. STOROSUM BWC, Mattila T, Wohlfarth TD, Gispen-de Wied CC, et al
    Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies.
    Psychiatry Res. 2022;320:114997.
    PubMed     Abstract available

  163. ELLINI S, Romdhane IB, Bougacha D, Abassi A, et al
    COVID-19 induced psychosis: A case report.
    Psychiatry Res. 2022;320:115009.

  164. GARRIDO-TORRES N, Alameda L, Rocha-Gonzalez I, Canal-Rivero M, et al
    Response to the letter to editor regarding "Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain".
    Psychiatry Res. 2022;322:115008.

  165. MANNARINI S, Taccini F, Sato I, Rossi AA, et al
    Understanding stigma toward schizophrenia.
    Psychiatry Res. 2022;318:114970.
    PubMed     Abstract available

  166. SOMMER IE, N de Boer J
    How to reap the benefits of language for psychiatry.
    Psychiatry Res. 2022;318:114932.
    PubMed     Abstract available

    November 2022
  167. ROSEN RL, Ramasubramani RS, Benowitz NL, Gandhi KK, et al
    Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
    Psychiatry Res. 2022;319:114989.
    PubMed     Abstract available

    Clinical genetics of schizophrenia and related neuropsychiatric disorders.
    Psychiatry Res. 2022;319:114992.
    PubMed     Abstract available

  169. DUDLEY R, Watson F, O'Grady L, Aynsworth C, et al
    Prevalence and nature of multi-sensory and multi-modal hallucinations in people with first episode psychosis.
    Psychiatry Res. 2022;319:114988.
    PubMed     Abstract available

  170. LAHTI AC
    Discovery of early schizophrenia through neuroimaging.
    Psychiatry Res. 2022;322:114993.
    PubMed     Abstract available

  171. CELLA M, Sedgwick O, Lawrence M, Grant N, et al
    Evaluating the mechanisms of social cognition intervention in schizophrenia: A proof-of-concept trial.
    Psychiatry Res. 2022;319:114963.
    PubMed     Abstract available

  172. TAO TJ, Hui CLM, Hui PWM, Ho ECN, et al
    Working memory deterioration as an early warning sign for relapse in remitted psychosis: A one-year naturalistic follow-up study.
    Psychiatry Res. 2022;319:114976.
    PubMed     Abstract available

  173. XIE Y, Guan M, Cai Y, Wang Z, et al
    Impact of low-frequency repetitive transcranial magnetic stimulation on functional network connectivity in schizophrenia patients with auditory verbal hallucinations.
    Psychiatry Res. 2022;320:114974.
    PubMed     Abstract available

    Social anhedonia and other indicators of risk for schizophrenia: Theory and inquiry.
    Psychiatry Res. 2022;319:114966.
    PubMed     Abstract available

  175. CHA M, Al-Chalabi N, Qian J, Chaudhary Z, et al
    Concordance between the Columbia-Suicide Severity Rating Scale and Beck Scale for Suicide Ideation in assessing suicide behaviour in young adults with schizophrenia spectrum disorders.
    Psychiatry Res. 2022;319:114965.
    PubMed     Abstract available

  176. LV H, Li J, Gao K, Zeng L, et al
    Identification of genetic loci that overlap between schizophrenia and metabolic syndrome.
    Psychiatry Res. 2022;318:114947.
    PubMed     Abstract available

  177. RUIZ-DELGADO I, Moreno-Kustner B, Garcia-Medina M, Barrigon ML, et al
    Is Metacognitive Training effective for improving neurocognitive function in patients with a recent onset of psychosis?
    Psychiatry Res. 2022;318:114941.
    PubMed     Abstract available

  178. SCHWAB SG
    Genetic variation and susceptibility to schizophrenia: Work in progress.
    Psychiatry Res. 2022;318:114949.
    PubMed     Abstract available

  179. ZHANG Q, Huo JH, Guo L, Wang L, et al
    Common and rare variants within SP4 exert distinct molecular mechanisms contributing to the risk of schizophrenia.
    Psychiatry Res. 2022;318:114948.

  180. LU W, Srijeyanthan J, Mueser KT, Yanos PT, et al
    Predictors of undocumented PTSD in persons using public mental health services.
    Psychiatry Res. 2022;317:114892.
    PubMed     Abstract available

  181. KIM WS, Heo DW, Shen J, Tsogt U, et al
    Altered functional connectivity in psychotic disorder not otherwise specified.
    Psychiatry Res. 2022;317:114871.
    PubMed     Abstract available

  182. LANGLOIS T, Sanchez-Rodriguez R, Bourcier A, Lamy P, et al
    "Accept voices(c)" group intervention for the management of auditory verbal hallucinations-results at 6 and 12 months.
    Psychiatry Res. 2022;317:114860.
    PubMed     Abstract available

  183. RIHAL V, Khan H, Kaur A, Singh TG, et al
    Therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders.
    Psychiatry Res. 2022;317:114782.
    PubMed     Abstract available

    October 2022
  184. ZHANG T, Zeng J, Wei Y, Ye J, et al
    Changes in inflammatory balance correlates with conversion to psychosis among individuals at clinical high-risk: A prospective cohort study.
    Psychiatry Res. 2022;318:114938.
    PubMed     Abstract available

  185. SCHELIGA S, Schwank R, Scholle R, Habel U, et al
    A neural mechanism underlying predictive visual motion processing in patients with schizophrenia.
    Psychiatry Res. 2022;318:114934.
    PubMed     Abstract available

  186. CUESTA MJ, Sanchez-Torres AM, Moreno-Izco L, Garcia de Jalon E, et al
    Neurocognitive correlates of the varied domains of outcomes at 20 year follow-up of first-episode psychosis.
    Psychiatry Res. 2022;318:114933.
    PubMed     Abstract available

  187. ENDRES D, Lerchenmuller V, Runge K, von Zedtwitz K, et al
    Anti-astrocytic autoantibody patterns in the cerebrospinal fluid of patients with depression and psychosis.
    Psychiatry Res. 2022;317:114905.
    PubMed     Abstract available

  188. GIZDIC A, Baxter T, Barrantes-Vidal N, Park S, et al
    Loneliness and psychosocial predictors of psychosis-proneness during COVID-19: Preliminary findings from Croatia.
    Psychiatry Res. 2022;317:114900.
    PubMed     Abstract available

  189. DEAN B, Thomas EHX, Bozaoglu K, Tan EJ, et al
    Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology.
    Psychiatry Res. 2022;317:114873.
    PubMed     Abstract available

  190. PELIZZA L, Quattrone E, Leuci E, Paulillo G, et al
    Anxious-depressive symptoms after a first episode of schizophrenia: Response to treatment and psychopathological considerations from the 2-year "Parma Early Psychosis" program.
    Psychiatry Res. 2022;317:114887.
    PubMed     Abstract available

  191. BARLATI S, Nibbio G, Bianchi F, Gigli EBL, et al
    Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
    Psychiatry Res. 2022;317:114878.
    PubMed     Abstract available

  192. DOKUZ G, Kani AS, Uysal O, Kuscu MK, et al
    The impact of childhood trauma and daily life experiences on emotional and psychotic symptom intensity in psychosis: An experience sampling study.
    Psychiatry Res. 2022;317:114872.
    PubMed     Abstract available

    September 2022
    From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis.
    Psychiatry Res. 2022;317:114866.
    PubMed     Abstract available

  194. MORITZ S, Goritz AS, Franz C, Sibilis A, et al
    Whodunit - A novel video-based task for the measurement of jumping to conclusions in the schizophrenia spectrum.
    Psychiatry Res. 2022;317:114862.
    PubMed     Abstract available

  195. WALKER E
    The permeable boundary between biological and psychological processes in the origins of psychosis.
    Psychiatry Res. 2022;317:114853.
    PubMed     Abstract available

    A sisters search for the seeds of psychosis.
    Psychiatry Res. 2022;317:114846.
    PubMed     Abstract available

  197. SNELLEKSZ M, Rossell SL, Gibbons A, Nithianantharajah J, et al
    Evidence that the frontal pole has a significant role in the pathophysiology of schizophrenia.
    Psychiatry Res. 2022;317:114850.
    PubMed     Abstract available

  198. YAO L, Liu H, Tian X
    Medication adherence among community-dwelling schizophrenia patients during the COVID-19 pandemic: A cross-sectional study.
    Psychiatry Res. 2022;317:114841.
    PubMed     Abstract available

    August 2022
  199. KOOPOWITZ SM, Cotton SM, Uhlmann A, Thomas KGF, et al
    Executive function in methamphetamine users with and without psychosis.
    Psychiatry Res. 2022;317:114820.
    PubMed     Abstract available

  200. BIZUMIC B, Gunningham B, Christensen BK
    Prejudice towards people with mental illness, schizophrenia, and depression among mental health professionals and the general population.
    Psychiatry Res. 2022;317:114817.
    PubMed     Abstract available

  201. EATON WW, Rodriguez KM, Thomas MA, Johnson J, et al
    Immunologic profiling in schizophrenia and rheumatoid arthritis.
    Psychiatry Res. 2022;317:114812.
    PubMed     Abstract available

  202. BARANOVA A, Cao H, Zhang F
    Severe COVID-19 increases the risk of schizophrenia.
    Psychiatry Res. 2022;317:114809.
    PubMed     Abstract available

  203. MCCARTHY JM, Wood AJ, Shinners MG, Heinrich H, et al
    Pilot development and feasibility of telehealth Community Reinforcement and Family Training (CRAFT) for early psychosis and substance use.
    Psychiatry Res. 2022;317:114804.
    PubMed     Abstract available

  204. HU M, Xia Y, Zong X, Sweeney JA, et al
    Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes.
    Psychiatry Res. 2022;317:114789.
    PubMed     Abstract available

  205. LYNCH DA, Brown M, Saperstein A, Stefancic A, et al
    Assessing metamotivation in schizophrenia: A pilot study of the Brief Regulation of Motivation Scale (BRoMS).
    Psychiatry Res. 2022;317:114799.
    PubMed     Abstract available

  206. LI Z, Chen X
    Comprehensive analysis of shared genetic loci between hippocampal volume and schizophrenia.
    Psychiatry Res. 2022;316:114795.
    PubMed     Abstract available

  207. TIKKANEN V, Siira V, Wahlberg KE, Hakko H, et al
    Deficits in adolescent social functioning, dysfunctional family processes and genetic risk for schizophrenia spectrum disorders as risk factors for later psychiatric morbidity of adoptees.
    Psychiatry Res. 2022;316:114793.
    PubMed     Abstract available

  208. LIU CM, Liu CC, Hsieh MH, Hwang TJ, et al
    The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis.
    Psychiatry Res. 2022;316:114775.
    PubMed     Abstract available

  209. HERPERTZ J, Richter MF, Barkhau C, Storck M, et al
    Symptom monitoring based on digital data collection during inpatient treatment of schizophrenia spectrum disorders - A feasibility study.
    Psychiatry Res. 2022;316:114773.
    PubMed     Abstract available

  210. CAI H, Zeng C, Zhang X, Liu Y, et al
    Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study.
    Psychiatry Res. 2022;316:114762.
    PubMed     Abstract available

  211. KOOL L, Oranje B, Meijs H, De Wilde B, et al
    Event-related potentials and use of psychotropic medication in major psychiatric disorders.
    Psychiatry Res. 2022;314:114637.
    PubMed     Abstract available

  212. PUJOL N, Berge D, Mane A, Bioque M, et al
    The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: Results from a 2-year follow-up study.
    Psychiatry Res. 2022;316:114760.
    PubMed     Abstract available

    July 2022
  213. SALEHI A, Namaei P, TaghaviZanjani F, Bagheri S, et al
    Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
    Psychiatry Res. 2022;316:114737.
    PubMed     Abstract available

  214. DESAI SS, Nguyen AL, Bernstein GA
    Letter to editor: Case report of long COVID-19 with psychosis in a child.
    Psychiatry Res. 2022;316:114743.

  215. SEEMAN MV
    Sex/Gender differences in schizophrenia: Thinking back and thinking forward.
    Psychiatry Res. 2022;316:114738.
    PubMed     Abstract available

  216. DADERWAL MC, Sreeraj VS, Suhas S, Rao NP, et al
    Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia.
    Psychiatry Res. 2022;316:114731.
    PubMed     Abstract available

  217. GALLIOT G, Sanchez-Rodriguez R, Belloc A, Phulpin H, et al
    Is clinical insight a determinant factor of subjective recovery in persons living with schizophrenia or schizoaffective disorders?
    Psychiatry Res. 2022;316:114726.
    PubMed     Abstract available

  218. PARK HJ, Kang WS, Oh M, Kim JW, et al
    Association of the promoter haplotype in CDK5 gene with schizophrenia in a Korean population.
    Psychiatry Res. 2022;316:114723.

  219. RIBOLSI M, Albergo G, Fiori Nastro F, Pelle M, et al
    Autistic symptomatology in UHR patients: A preliminary report.
    Psychiatry Res. 2022;313:114634.
    PubMed     Abstract available

  220. NGUYEN T, Frayne J, Watson S, Lebedevs T, et al
    Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital.
    Psychiatry Res. 2022;313:114614.
    PubMed     Abstract available

    June 2022
  221. DIAGO M, Vila-Badia R, Serra-Arumi C, Butjosa A, et al
    Emotional abuse and perceived stress: The most relevant factors in suicide behavior in first-episode psychosis patients.
    Psychiatry Res. 2022;315:114699.
    PubMed     Abstract available

  222. JEREMIAN R, Malinowski A, Chaudhary Z, Srivastava A, et al
    Epigenetic age dysregulation in individuals with bipolar disorder and schizophrenia.
    Psychiatry Res. 2022;315:114689.
    PubMed     Abstract available

  223. RAMAIN J, Conus P, Golay P
    Grouping affective psychoses in early intervention: Justification for specific treatment guidelines.
    Psychiatry Res. 2022;314:114690.
    PubMed     Abstract available

  224. ZARBO C, Agosta S, Casiraghi L, De Novellis A, et al
    Assessing adherence to and usability of Experience Sampling Method (ESM) and actigraph in patients with Schizophrenia Spectrum Disorder: A mixed-method study.
    Psychiatry Res. 2022;314:114675.
    PubMed     Abstract available

    May 2022
  225. LI Z, Li X, Jin M, Liu Y, et al
    Identification of potential biomarkers and their correlation with immune infiltration cells in schizophrenia using combinative bioinformatics strategy.
    Psychiatry Res. 2022;314:114658.
    PubMed     Abstract available

  226. SHIMADA T, Ito S, Makabe A, Yamanushi A, et al
    Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis.
    Psychiatry Res. 2022;314:114656.
    PubMed     Abstract available

  227. KIRSCHENBAUM MA, Lopez LV, de Filippis R, Ali AF, et al
    Validation of a novel Psychosis-Implicit Association Test (P-IAT) as a diagnostic support tool.
    Psychiatry Res. 2022;314:114647.
    PubMed     Abstract available

  228. BHATTACHARYYA U, Bhatia T, Deshpande SN, Thelma BK, et al
    Genetic variations in evolutionary accelerated regions disrupt cognition in schizophrenia.
    Psychiatry Res. 2022;314:114586.
    PubMed     Abstract available

  229. XU L, Hao D, Wei Y, Cui H, et al
    Effect of cognitive insight on clinical insight from pre-morbid to early psychosis stages.
    Psychiatry Res. 2022;313:114613.
    PubMed     Abstract available

  230. CAO X, Chen S, Xu H, Wang Q, et al
    Global functioning, cognitive function, psychopathological symptoms in untreated patients with first-episode schizophrenia: A cross-sectional study.
    Psychiatry Res. 2022;313:114616.
    PubMed     Abstract available

  231. LONG J, Tian L, Baranova A, Cao H, et al
    Convergent lines of evidence supporting involvement of NFKB1 in schizophrenia.
    Psychiatry Res. 2022;312:114588.
    PubMed     Abstract available

  232. KATZ IR, Szymanski BR, Marder SR, Shotwell A, et al
    Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications.
    Psychiatry Res. 2022;313:114590.
    PubMed     Abstract available

    April 2022
  233. THAI H, Robertson C, Friberg L, Hatko A, et al
    WHODAS 2.0: Associations of functional disability with sex, age, and length of care in outpatients with schizophrenia-spectrum disorders.
    Psychiatry Res. 2022;313:114583.
    PubMed     Abstract available

  234. MARTINS PS, Caldas F, Oliveira C, Mota J, et al
    A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder.
    Psychiatry Res. 2022;312:114581.
    PubMed     Abstract available

  235. LI X, Yuan X, Pang L, Zhang S, et al
    nThe effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naive, first episode schizophrenia patients.
    Psychiatry Res. 2022;313:114582.
    PubMed     Abstract available

  236. XU Y, Cai Z, Fang C, Zheng J, et al
    Impact of aerobic exercise on cognitive function in patients with schizophrenia during daily care: A meta-analysis.
    Psychiatry Res. 2022;312:114560.
    PubMed     Abstract available

  237. OUYANG H, Huang M, Chen S, Wu X, et al
    Peripheral lower triiodothyronine levels related to interleukin-6 in patients with first-episode schizophrenia.
    Psychiatry Res. 2022;312:114546.

  238. WELCH KG, Stiles BJ, Palsson OS, Meyer-Kalos PS, et al
    The use of diary methods to evaluate daily experiences in first-episode psychosis.
    Psychiatry Res. 2022;312:114548.
    PubMed     Abstract available

  239. GONZALEZ-RODRIGUEZ A, Monreal JA, Porras-Segovia A, Cervilla JA, et al
    Psychometric instruments for the assessment of depressive symptoms in patients with delusional disorder: A systematic review.
    Psychiatry Res. 2022;310:114435.
    PubMed     Abstract available

    March 2022
  240. JAISWAL N, Kar SK, Gupta PK
    Comments on "High frequency repetitive transcranial magnetic stimulation of dorsomedial prefrontal cortex for negative symptoms in patients with schizophrenia: A double-blind, randomized controlled trial".
    Psychiatry Res. 2022;312:114532.

  241. PANDOLFO G, Genovese G, Bruno A, Campolo D, et al
    Advanced glycation end-products and advanced oxidation protein products in schizophrenia.
    Psychiatry Res. 2022;311:114527.
    PubMed     Abstract available

  242. LI J, Zhang X, Jiang J, Zhang B, et al
    Comparison of electroconvulsive therapy and magnetic seizure therapy in schizophrenia: Structural changes/neuroplasticity.
    Psychiatry Res. 2022;312:114523.
    PubMed     Abstract available

  243. BORNHEIMER LA, Li Verdugo J, Holzworth J, Im V, et al
    Modifying a cognitive behavioral suicide prevention treatment for adults with schizophrenia spectrum disorders in community mental health.
    Psychiatry Res. 2022;311:114505.
    PubMed     Abstract available

  244. XU X, Shao G, Zhang X, Hu Y, et al
    The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: A systematic review and network meta-analysis.
    Psychiatry Res. 2022;311:114500.
    PubMed     Abstract available

  245. RAMMOUZ I, Bouri S, Merzouki M, Berraho MA, et al
    Reliability of self-report of cannabis use among patients with schizophrenia.
    Psychiatry Res. 2022;311:114491.

  246. KEMPPAINEN A, Lindgren M, Suvisaari J, Kieseppa T, et al
    Adverse childhood experiences and social and occupational functioning in first-episode psychosis - A one year follow - up.
    Psychiatry Res. 2022;311:114502.

  247. MUNIR K, Oner O, Kerala C, Rustamov I, et al
    Social distance and stigma towards persons with serious mental illness among medical students in five European Central Asia countries.
    Psychiatry Res. 2022;309:114409.
    PubMed     Abstract available

    February 2022
  248. GOHARI E, Moore RC, Depp CA, Ackerman RA, et al
    Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study.
    Psychiatry Res. 2022;310:114487.
    PubMed     Abstract available

  249. LIU Y, Jia LN, Wu H, Jiang W, et al
    Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia.
    Psychiatry Res. 2022;311:114484.

  250. COWAN T, Cohen AS, Raugh IM, Strauss GP, et al
    Ambulatory audio and video recording for digital phenotyping in schizophrenia: Adherence & data usability.
    Psychiatry Res. 2022;311:114485.
    PubMed     Abstract available

  251. SANTESTEBAN-ECHARRI O, Sandel D, Liu L, Bearden CE, et al
    Family history of psychosis in youth at clinical high risk: A replication study.
    Psychiatry Res. 2022;311:114480.
    PubMed     Abstract available

  252. MORIKAWA R, Watanabe Y, Igeta H, Arta RK, et al
    Novel missense SETD1A variants in Japanese patients with schizophrenia: Resequencing and association analysis.
    Psychiatry Res. 2022;310:114481.
    PubMed     Abstract available

  253. RODRIGUEZ M, Knizkova K, Kerkova B, Sironova A, et al
    The relationships between cognitive reserve, cognitive functioning and quality of life in first-episode schizophrenia spectrum disorders.
    Psychiatry Res. 2022;310:114479.
    PubMed     Abstract available

  254. LEE HS, Rast C, Shenoy S, Dean D, et al
    A meta-analytic review of transcranial direct current stimulation (tDCS) on general psychopathology symptoms of schizophrenia; immediate improvement followed by a return to baseline.
    Psychiatry Res. 2022;310:114471.
    PubMed     Abstract available

  255. SONG W, Lin GN, Yu S, Zhao M, et al
    Genome-wide identification of the shared genetic basis of cannabis and cigarette smoking and schizophrenia implicates NCAM1 and neuronal abnormality.
    Psychiatry Res. 2022;310:114453.
    PubMed     Abstract available

  256. TAN EJ, Toh WL, Rossell SL
    Examining relationships between state and trait psychotic symptoms and quality of life in schizophrenia spectrum disorders.
    Psychiatry Res. 2022;310:114450.
    PubMed     Abstract available

  257. LOPEZ-NAVARRO E, Fonseca-Pedrero E, Errasti J, Al-Halabi S, et al
    Mindfulness improves theory of mind in people experiencing psychosis: A pilot randomized clinical trial.
    Psychiatry Res. 2022;310:114440.
    PubMed     Abstract available

  258. GOH XX, Tang PY, Tee SF
    Effects of antipsychotics on antioxidant defence system in patients with schizophrenia: A meta-analysis.
    Psychiatry Res. 2022;309:114429.
    PubMed     Abstract available

  259. SCHWARTZ EK, Le TP, Cohen AS
    Sharing positive events: Ecological momentary assessment of emotion regulation via social capitalization in schizotypy.
    Psychiatry Res. 2022;308:114377.
    PubMed     Abstract available

  260. GROENMAN AP, van der Werf S, Geurts HM
    Subjective cognition in adults with common psychiatric classifications; a systematic review.
    Psychiatry Res. 2022;308:114374.
    PubMed     Abstract available

    January 2022
  261. JEONG JH, Kim SW, Lee BJ, Kim JJ, et al
    The factor structure and clinical utility of clinician-rated dimensions of psychosis symptom severity in patients with recent-onset psychosis: Results of a 1-year longitudinal follow-up prospective cohort study.
    Psychiatry Res. 2022;310:114420.
    PubMed     Abstract available

  262. BARTOLI F, Cavaleri D, Callovini T, Riboldi I, et al
    Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.
    Psychiatry Res. 2022;309:114405.
    PubMed     Abstract available

  263. LUNDIN NB, Jones MN, Myers EJ, Breier A, et al
    Semantic and phonetic similarity of verbal fluency responses in early-stage psychosis.
    Psychiatry Res. 2022;309:114404.
    PubMed     Abstract available

  264. XIE Y, He Y, Guan M, Wang Z, et al
    Low-frequency rTMS treatment alters the topographical organization of functional brain networks in schizophrenia patients with auditory verbal hallucination.
    Psychiatry Res. 2022;309:114393.
    PubMed     Abstract available

  265. RAULT O, Lamothe H, Pelissolo A
    Therapeutic use of virtual reality relaxation in schizophrenia: A pilot study.
    Psychiatry Res. 2022;309:114389.
    PubMed     Abstract available

  266. VERDOUX H, Sibert A, Quiles C
    Trauma and resistance to antipsychotic treatment in schizophrenia: A narrative review.
    Psychiatry Res. 2022;309:114392.
    PubMed     Abstract available

  267. MORAN LV, Tsang ES, Ongur D, Hsu J, et al
    Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: Submit to: Psychiatry Research.
    Psychiatry Res. 2022;308:114387.
    PubMed     Abstract available

  268. SINGH A, Kumar V, Pathak H, Jacob AA, et al
    Effect of antipsychotic dose reduction on cognitive function in schizophrenia.
    Psychiatry Res. 2022;308:114383.
    PubMed     Abstract available

  269. GANDHI A, Mote J, Fulford D
    A transdiagnostic meta-analysis of physical and social Anhedonia in major depressive disorder and schizophrenia spectrum disorders.
    Psychiatry Res. 2022;309:114379.
    PubMed     Abstract available

    December 2021
  270. LABONTE C, Zhand N, Park A, Harvey PD, et al
    Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation.
    Psychiatry Res. 2021;308:114382.
    PubMed     Abstract available

  271. GICAS KM, Parmar PK, Fabiano GF, Mashhadi F, et al
    Substance-induced psychosis and cognitive functioning: A systematic review.
    Psychiatry Res. 2021;308:114361.
    PubMed     Abstract available

  272. GARRIDO-TORRES N, Suarez-Suarez ML, Rocha-Gonzalez I, Alameda L, et al
    Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain.
    Psychiatry Res. 2021;308:114352.
    PubMed     Abstract available

  273. VERU F, MacDonald K, Malla A, Pruessner M, et al
    The effects of childhood adversity on treatment delays and its components in first-episode psychosis.
    Psychiatry Res. 2021;308:114341.
    PubMed     Abstract available

  274. LAVAUD P, McMahon K, Sanchez Rico M, Hanon C, et al
    Long-term care utilization within older adults with schizophrenia: Associated factors in a multicenter study.
    Psychiatry Res. 2021;308:114339.
    PubMed     Abstract available

  275. LIU X, Wang D, Fan R, Wang R, et al
    Life expectancy and potential years of life lost for schizophrenia in western China.
    Psychiatry Res. 2021;308:114330.
    PubMed     Abstract available

  276. LOCKWOOD L, Miller B, Youssef NA
    Epigenetics and first-episode psychosis: A systematic review.
    Psychiatry Res. 2021;307:114325.
    PubMed     Abstract available

  277. THOMPSON EC, Visser KF, Schiffman J, Spirito A, et al
    Preliminary evidence supporting the practice of psychosis-risk screening within an inpatient psychiatric setting serving adolescents.
    Psychiatry Res. 2021;307:114322.
    PubMed     Abstract available

  278. LEE S, Schwartz S
    Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies.
    Psychiatry Res. 2021;306:114277.
    PubMed     Abstract available

    November 2021
  279. LOCH AA, Mota NB, Rossler W, Gattaz WF, et al
    Exacerbation of psychosis risk during the COVID-19 pandemic: The disproportionate impact on the lower income population.
    Psychiatry Res. 2021;307:114319.

  280. ALLIENDE LM, Czepielewski LS, Aceituno D, Castaneda CP, et al
    Gender, age and geographical representation over the past 50 years of schizophrenia research.
    Psychiatry Res. 2021;307:114279.
    PubMed     Abstract available

  281. FERNANDEZ DK, Deane FP, Vella SA
    Effects of online continuum and categorical belief manipulations on schizophrenia stigma, help-seeking, and help-provision.
    Psychiatry Res. 2021;307:114293.
    PubMed     Abstract available

  282. CHEN S, Tang Y, Fan X, Qiao Y, et al
    The role of white matter abnormality in the left anterior corona radiata: In relation to formal thought disorder in patients with schizophrenia.
    Psychiatry Res. 2021;307:114302.
    PubMed     Abstract available

  283. GOU N, Xiang Y, Zhou J, Zhang S, et al
    Identification of violent patients with schizophrenia using a hybrid machine learning approach at the individual level.
    Psychiatry Res. 2021;306:114294.
    PubMed     Abstract available

  284. LAI M, Hegde R, Kelly S, Bannai D, et al
    Investigating sleep spindle density and schizophrenia: A meta-analysis.
    Psychiatry Res. 2021;307:114265.
    PubMed     Abstract available

  285. BARR SM, Roberts D, Thakkar KN
    Psychosis in transgender and gender non-conforming individuals: A review of the literature and a call for more research.
    Psychiatry Res. 2021;306:114272.
    PubMed     Abstract available

  286. LYU J, Zhang J
    Suicide means, timing, intent and behavior characteristics of the suicides with schizophrenia.
    Psychiatry Res. 2021;306:114267.
    PubMed     Abstract available

  287. RUSSO M, Consoli S, De Rosa MA, Calisi D, et al
    A case of Sars-Cov-2-related mania with prominent psychosis>.
    Psychiatry Res. 2021;306:114266.

  288. GALLOS IK, Mantonakis L, Spilioti E, Kattoulas E, et al
    The relation of integrated psychological therapy to resting state functional brain connectivity networks in patients with schizophrenia.
    Psychiatry Res. 2021;306:114270.
    PubMed     Abstract available

  289. SANTOS MJ, Ferreira TF, Sequeira M, Trancas B, et al
    Chronic hallucinatory psychosis presenting with olfactory hallucinations: A case report.
    Psychiatry Res. 2021;305:114262.

  290. SAHYOUNI C, Hefazi E
    Clozapine induced pericarditis: A case report.
    Psychiatry Res. 2021;305:114250.
    PubMed     Abstract available

  291. SHROITMAN NK, Peles E, Even-Tov S, Schreiber S, et al
    False-positive fentanyl screening kit results during treatment with long term injectable risperidone (Risperdal-Consta).
    Psychiatry Res. 2021;305:114246.
    PubMed     Abstract available

  292. RICHARDSON N, Greenway SC, Bousman CA
    Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review.
    Psychiatry Res. 2021;305:114247.
    PubMed     Abstract available

  293. BRASSO C, Cisotto M, Ghirardini C, Pennazio F, et al
    Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward.
    Psychiatry Res. 2021;305:114214.
    PubMed     Abstract available

  294. GROT S, Giguere CE, Smine S, Mongeau-Perusse V, et al
    Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy.
    Psychiatry Res. 2021;305:114199.
    PubMed     Abstract available

  295. MILLER BJ, McCall WV, McEvoy JP, Lu XY, et al
    Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
    Psychiatry Res. 2021;305:114195.
    PubMed     Abstract available

    October 2021
  296. MENON V, Suhas S, Sethi MIS, Varadharajan N, et al
    Comments on the paper published by Lyu et al on Risk Factors for Suicide in People with Schizophrenia.
    Psychiatry Res. 2021;306:114255.

  297. DAMIANO RF, Avrichir BS, Melzer-Ribeiro DL, Sallet PC, et al
    Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-report.
    Psychiatry Res. 2021;305:114248.
    PubMed     Abstract available

  298. PAWELCZYK A, Lojek E, Radek M, Pawelczyk T, et al
    Prosodic deficits and interpersonal difficulties in patients with schizophrenia.
    Psychiatry Res. 2021;306:114244.
    PubMed     Abstract available

  299. LUO X, Zhang L, Zhang J, Chen H, et al
    Changes in the cognitive function of Chinese college students with a clinical high risk of psychosis.
    Psychiatry Res. 2021;305:114242.
    PubMed     Abstract available

  300. CLAYSON PE, Molina JL, Joshi YB, Thomas ML, et al
    Evaluation of the frequency following response as a predictive biomarker of response to cognitive training in schizophrenia.
    Psychiatry Res. 2021;305:114239.
    PubMed     Abstract available

  301. JIANG W, Rootes-Murdy K, Chen J, Bizzozero NIP, et al
    Multivariate alterations in insula - Medial prefrontal cortex linked to genetics in 12q24 in schizophrenia.
    Psychiatry Res. 2021;306:114237.
    PubMed     Abstract available

  302. SANCHEZ MC, Escurriola MF, Sanmartin MIF, Solntseva I, et al
    Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: A cohort study in primary care.
    Psychiatry Res. 2021;306:114233.
    PubMed     Abstract available

  303. BRYCE S, Zbukvic I, Wood SJ, Allott K, et al
    Cognitive remediation to address impairment in schizophrenia: Moving beyond effectiveness and toward implementation.
    Psychiatry Res. 2021;305:114232.

  304. MINICHINO A, Singh F, Pineda J, Friederich E, et al
    Corrigendum to 'Biological Motion induced mu suppression is reduced in Early Psychosis (EP) patients with active negative symptoms and Autism Spectrum Disorders (ASD)' [Psychiatry Research 238 (2016) 374-377].
    Psychiatry Res. 2021;306:114177.

  305. SARZYNSKA-WAWER J, Wawer A, Pawlak A, Szymanowska J, et al
    Detecting formal thought disorder by deep contextualized word representations.
    Psychiatry Res. 2021;304:114135.
    PubMed     Abstract available

    September 2021
  306. LUDTKE T, Ruegg N, Moritz S, Berger T, et al
    Insight and the number of completed modules predict a reduction of positive symptoms in an Internet-based intervention for people with psychosis.
    Psychiatry Res. 2021;306:114223.
    PubMed     Abstract available

  307. ZOU DS, Cowan HR, Azis M, Mittal VA, et al
    Reciprocal Social Behavior and Related Social Outcomes in Individuals at Clinical High Risk for Psychosis.
    Psychiatry Res. 2021;306:114224.
    PubMed     Abstract available

  308. SRIVASTAVA A, Dada O, Qian J, Al-Chalabi N, et al
    Epigenetics of Schizophrenia.
    Psychiatry Res. 2021;305:114218.
    PubMed     Abstract available

  309. FERNANDO R, Gan L, Xiao J, Yun Y, et al
    Hyperprolactinemia induced by brexpiprazole in patients with schizophrenia: A case report.
    Psychiatry Res. 2021;305:114215.

  310. HOMMAN LE, Smart SE, O'Neill F, MacCabe JH, et al
    Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration.
    Psychiatry Res. 2021;305:114211.
    PubMed     Abstract available

  311. MISHRA A, Soni AB, Umate MS, Andrade C, et al
    An exploratory evaluation of predictors of duration of untreated psychosis in first-episode psychosis in lower income patients.
    Psychiatry Res. 2021;305:114203.
    PubMed     Abstract available

  312. ZHU L, Zhang W, Zhu Y, Mu X, et al
    Cerebellar theta burst stimulation for the treatment of negative symptoms of schizophrenia: A multicenter, double-blind, randomized controlled trial.
    Psychiatry Res. 2021;305:114204.
    PubMed     Abstract available

  313. SHOSHINA II, Hovis JK, Felisberti FM, Santos NA, et al
    Visual processing and BDNF levels in first-episode schizophrenia.
    Psychiatry Res. 2021;305:114200.
    PubMed     Abstract available

  314. RABINOWITZ J, Rabinowitz AA
    Outlier-response pattern checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS).
    Psychiatry Res. 2021;303:114114.
    PubMed     Abstract available

  315. VALERIO KE, Jonas KG, Perlman G, Bromet EJ, et al
    A comparison of cognitive performance in the Suffolk County cohort and their unaffected siblings.
    Psychiatry Res. 2021;303:114111.
    PubMed     Abstract available

    August 2021
  316. KARTALCI S, Erbay MF, Kahraman A, Candir F, et al
    Evaluation of CSF flow dynamics in patients with schizophrenia using phase-contrast cine MRI.
    Psychiatry Res. 2021;304:114172.
    PubMed     Abstract available

  317. REINFELD S, Caceda R, Gil R, Strom H, et al
    Can new onset psychosis occur after mRNA based COVID-19 vaccine administration? A case report.
    Psychiatry Res. 2021;304:114165.

  318. LYU J, Zhang J, Hennessy DA
    Characteristics and Risk Factors for Suicide in People with Schizophrenia in Comparison to Those without Schizophrenia.
    Psychiatry Res. 2021;304:114166.
    PubMed     Abstract available

  319. YANG H, Xiao W, Yang M, Wang Y, et al
    Decreased neuregulin1beta1 in first episode and drug-naive patients with schizophrenia: Negative correlation with cognitive impairment.
    Psychiatry Res. 2021;304:114164.
    PubMed     Abstract available

  320. SAHIN D, Hever F, Bossert M, Herwig K, et al
    Early and middle latency auditory event-related potentials do not explain differences in neuropsychological performance between schizophrenia spectrum patients and matched healthy controls.
    Psychiatry Res. 2021;304:114162.
    PubMed     Abstract available

  321. DAURE C, Fortias M, Icick R, Delage C, et al
    Oral long acting antipsychotic penfluridol as a harm reduction treatment in a patient suffering from untreated schizophrenia and multiple drug dependence: A case report.
    Psychiatry Res. 2021;304:114147.
    PubMed     Abstract available

  322. DEYO C, Langdon R
    Cognitive correlates of 'Formal Thought Disorder' in a non-clinical sample with elevated schizotypal traits.
    Psychiatry Res. 2021;302:113971.
    PubMed     Abstract available

  323. BURNESS C, Corbet C, Beyene K, Webby C, et al
    Factors predicting high-dose and combined antipsychotic prescribing in New Zealand: High-dose antipsychotic prescribing.
    Psychiatry Res. 2021;302:113996.
    PubMed     Abstract available

    July 2021
  324. DA MOTTA C, Pato MT, Barreto Carvalho C, Castilho P, et al
    The neurocognitive and functional profile of schizophrenia in a genetically homogenous European sample.
    Psychiatry Res. 2021;304:114140.
    PubMed     Abstract available

  325. VOPPEL AE, de Boer JN, Brederoo SG, Schnack HG, et al
    Quantified language connectedness in schizophrenia-spectrum disorders.
    Psychiatry Res. 2021;304:114130.
    PubMed     Abstract available

  326. BOSNJAK KUHARIC D, Makaric P, Kekin I, Rossini Gajsak L, et al
    Changes of neurocognitive status in patients with the first-episode psychosis after 18 months of treatment-A prospective cohort study.
    Psychiatry Res. 2021;304:114131.
    PubMed     Abstract available

  327. GRACIA DFK, Gomes EMP, Coelho TA, Carriello M, et al
    Ficolin activation as a potential biomarker of the severity of schizophrenia.
    Psychiatry Res. 2021;304:114122.
    PubMed     Abstract available

  328. KU BS, Pauselli L, Covington MA, Compton MT, et al
    Computational linguistic analysis applied to a semantic fluency task: A replication among first-episode psychosis patients with and without derailment and tangentiality.
    Psychiatry Res. 2021;304:114105.
    PubMed     Abstract available

  329. SNELLEKSZ M, Dean B
    Lower levels of tubulin alpha 1b in the frontal pole in schizophrenia supports a role for changed cytoskeletal dynamics in the aetiology of the disorder.
    Psychiatry Res. 2021;303:114096.
    PubMed     Abstract available

  330. VASKINN A, Engelstad KN, Torgalsboen AK, Rund BR, et al
    Childhood trauma, social cognition and schizophrenia: Specific association between physical neglect and cognitive theory of mind in homicide offenders.
    Psychiatry Res. 2021;303:114093.
    PubMed     Abstract available

  331. JAGADHEESAN K, Danivas V, Itrat Q, Shekaran L, et al
    A 6-month study on the pattern of emergency department presentations for schizophrenia and other psychotic disorders during COVID-19 lockdown.
    Psychiatry Res. 2021;303:114081.
    PubMed     Abstract available

    June 2021
  332. CORBERA S, Wexler BE, Bell MD, Pearlson G, et al
    Predictors of social functioning and quality of life in schizophrenia and autism spectrum disorder.
    Psychiatry Res. 2021;303:114087.
    PubMed     Abstract available

  333. LI S, DeLisi LE, McDonough SI
    Rare germline variants in individuals diagnosed with schizophrenia within multiplex families.
    Psychiatry Res. 2021;303:114038.
    PubMed     Abstract available

  334. CASADO-ORTEGA A, Vila-Badia R, Butjosa A, Del Cacho N, et al
    Social cognition and its relationship with sociodemographic, clinical, and psychosocial variables in first-episode psychosis.
    Psychiatry Res. 2021;302:114040.
    PubMed     Abstract available

  335. ANDREOU D, Jorgensen KN, Wortinger LA, Engen K, et al
    Cytomegalovirus infection and IQ in patients with severe mental illness and healthy individuals.
    Psychiatry Res. 2021;300:113929.
    PubMed     Abstract available

  336. BRAUN D, Schlossmann J, Haen E
    Asymmetric dimethylarginine in psychiatric disorders.
    Psychiatry Res. 2021;300:113901.
    PubMed     Abstract available

    May 2021
  337. KELLY DL, Claxton A, Bidollari I, Du Y, et al
    Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
    Psychiatry Res. 2021;302:114030.
    PubMed     Abstract available

  338. GUILLAUME F, Thomas E
    Recollection and familiarity in schizophrenia:An ERP investigation using face recognition exclusion tasks.
    Psychiatry Res. 2021;302:113973.
    PubMed     Abstract available

  339. SCHEFFLER F, Phahladira L, Luckhoff H, du Plessis S, et al
    Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment.
    Psychiatry Res. 2021;302:114022.
    PubMed     Abstract available

  340. MUNOZ-SAMONS D, Tor J, Rodriguez-Pascual M, Alvarez-Subiela X, et al
    Recent stressful life events and stress sensitivity in children and adolescents at clinical risk for psychosis.
    Psychiatry Res. 2021;303:114017.
    PubMed     Abstract available

  341. HELLER C, Weiss T, Del Re EC, Swago S, et al
    Smaller subcortical volumes and enlarged lateral ventricles are associated with higher global functioning in young adults with 22q11.2 deletion syndrome with prodromal symptoms of schizophrenia.
    Psychiatry Res. 2021;301:113979.
    PubMed     Abstract available

  342. ABEL DB, Salyers MP, Wu W, Monette MA, et al
    Quality versus quantity: Determining real-world social functioning deficits in schizophrenia.
    Psychiatry Res. 2021;301:113980.
    PubMed     Abstract available

    April 2021
  343. ALBA L, Coll C, Saez S, Alonso L, et al
    New-onset psychosis: A case report of brief psychosis related to COVID-19 infection.
    Psychiatry Res. 2021;301:113975.

  344. UCOK A, Karakas B, Sahin OS
    Formal thought disorder in patients with first-episode schizophrenia: Results of a one-year follow-up study.
    Psychiatry Res. 2021;301:113972.
    PubMed     Abstract available

  345. Discrepancies between staff and gold standard ratings of schizophrenia symptom severity.
    Psychiatry Res. 2021;301:113963.

  346. DE PERI L, Deste G, Vita A
    Strucutural brain imaging at the onset of schizophrenia:What have we learned and what have we missed.
    Psychiatry Res. 2021;301:113962.
    PubMed     Abstract available

  347. MEDALIA A, Saperstein AM, Stefancic A, Meyler S, et al
    Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings.
    Psychiatry Res. 2021;301:113956.
    PubMed     Abstract available

  348. XIE YJ, Xi YB, Cui LB, Guan MZ, et al
    Functional connectivity of cerebellar dentate nucleus and cognitive impairments in patients with drug-naive and first-episode schizophrenia.
    Psychiatry Res. 2021;300:113937.
    PubMed     Abstract available

  349. PENNOU A, Lecomte T, Khazaal Y, Potvin S, et al
    Does theory of mind predict specific domains of social functioning in individuals following a first episode psychosis?
    Psychiatry Res. 2021;301:113933.
    PubMed     Abstract available

  350. WANG YY, Hsu SH, Tsai HY, Cheng MC, et al
    Sequencing of the coding regions of GNBIL on chromosome 22q11.2 as a risk gene of schizophrenia.
    Psychiatry Res. 2021;300:113943.
    PubMed     Abstract available

  351. SCHURHOFF F, Corfdir C, Pignon B, Lajnef M, et al
    No alteration of leukocyte telomere length in first episode psychosis.
    Psychiatry Res. 2021;301:113941.
    PubMed     Abstract available

  352. VAERNES TG, Rossberg JI, Melle I, Nelson B, et al
    Basic self-disturbance in subjects at clinical high risk for psychosis: Relationship with clinical and functional outcomes at one year follow-up.
    Psychiatry Res. 2021;300:113942.
    PubMed     Abstract available

  353. STRASSNIG MT, Miller ML, Moore R, Depp CA, et al
    Evidence for avolition in bipolar disorder? A 30-day ecological momentary assessment comparison of daily activities in bipolar disorder and schizophrenia.
    Psychiatry Res. 2021;300:113924.
    PubMed     Abstract available

  354. SIDDIQUI SV, Nizamie SH, Siddiqui MA, Jahan M, et al
    Evaluation of N-400 Evoked Response Potential in schizophrenia: An endophenotype or a disease marker?
    Psychiatry Res. 2021;300:113907.
    PubMed     Abstract available

    March 2021
  355. AU RWC, Sezto HNW, Lam VWM, Wan YT, et al
    Brief report: A randomized controlled trial of a compensatory cognitive training to improve prospective memory performance in people with schizophrenia or depression.
    Psychiatry Res. 2021;300:113914.
    PubMed     Abstract available

  356. LI M, Liu Y, Qiu Y, Zhang J, et al
    The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
    Psychiatry Res. 2021;300:113899.
    PubMed     Abstract available

  357. SIMON AE, Keller P, Cattapan K
    Commentary about social avoidance and its significance in adolescents and young adults.
    Psychiatry Res. 2021;297:113718.
    PubMed     Abstract available

  358. TOYODA K, Hata T, Yamauchi S, Kinoshita S, et al
    A descriptive study of 10-year clozapine use from the nationwide database in Japan.
    Psychiatry Res. 2021;297:113764.
    PubMed     Abstract available

  359. O'CONNOR C, Vaughan S
    Does selectively endorsing different approaches to treating mental illness affect lay beliefs about the cause and course of mental illness?
    Psychiatry Res. 2021;297:113726.
    PubMed     Abstract available

    February 2021
  360. SREERAJ VS, Holla B, Ithal D, Nadella RK, et al
    Psychiatric symptoms and syndromes transcending diagnostic boundaries in Indian multiplex families: The cohort of ADBS study.
    Psychiatry Res. 2021;296:113647.
    PubMed     Abstract available

  361. MORRIS E, Batallones R, Ryan J, Slomp C, et al
    Psychiatric genetic counseling for serious mental illness: Impact on psychopathology and psychotropic medication adherence.
    Psychiatry Res. 2021;296:113663.
    PubMed     Abstract available

  362. CAMUS D, Dan Glauser ES, Gholamrezaee M, Gasser J, et al
    Factors associated with repetitive violent behavior of psychiatric inpatients.
    Psychiatry Res. 2021;296:113643.
    PubMed     Abstract available

  363. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
    Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive symptoms.
    Psychiatry Res. 2021;296:113665.
    PubMed     Abstract available

  364. KHARE C, Mueser KT, Bahaley M, Vax S, et al
    Employment in people with severe mental illnesses receiving public sector psychiatric services in India.
    Psychiatry Res. 2021;296:113673.
    PubMed     Abstract available

    January 2021
  365. KETHARANATHAN T, Pereira A, Reets U, Walker D, et al
    Brain changes in NF-kappaB1 and epidermal growth factor system markers at peri-pubescence in the spiny mouse following maternal immune activation.
    Psychiatry Res. 2021;295:113564.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.